Last reviewed · How we verify
NCT03915795
Statins Study in Kawasaki Disease Children With Coronary Artery Abnormalities
trial in Kawasaki Disease in 30 participants. Completed in 30 December 2023.
31 January 2023
Quick facts
| Lead sponsor | Children's Hospital of Fudan University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 20 August 2019 |
| Primary completion | 31 January 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across China |
Conditions studied
- Kawasaki Disease — all drugs for Kawasaki Disease →
- Coronary Artery Abnormalities — all drugs for Coronary Artery Abnormalities →
Sponsor
Children's Hospital of Fudan University
Who can join
Adults 2 to 18, any sex, with Kawasaki Disease or Coronary Artery Abnormalities. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to investigate the effects of statins on chronic inflammation, coronary artery abnormalities and clinical cardiac events in long-term KD children complicated with severe coronary artery abnormalities, and the feasibility and safety of statins in treatment of KD children.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease.
Zhu F, Ang JY. · · 2021 · cited 27× · PMID 35194409 · DOI 10.1007/s11908-021-00746-1
Verify or expand the search:
- PubMed search for NCT03915795
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kawasaki Disease
Currently open trials in the same condition.
- NCT05643651 — Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease · Phase 4 · recruiting
- NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting
- NCT07291245 — Kawasaki MATCH Trial · NA · recruiting
- NCT06978439 — Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease · Phase 4 · recruiting
- NCT06993636 — Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years · recruiting
Other Children's Hospital of Fudan University trials
Trials by the same sponsor.
- NCT04955821 — Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS · not yet recruiting
- NCT05862688 — A Cohort Study on Anti-microbial Stewardship in PICU · not yet recruiting
- NCT05595239 — Blood Purification in Septic Children · NA · not yet recruiting
- NCT07325903 — Research of Integrated Traditional Chinese and Western Medicine on Precocious Puberty · EARLY_PHASE1 · not yet recruiting
- NCT07141615 — Clinical Observation of Qingwei Huazhuo Decoction (Product: Jinsaiyu) in Improving Children With Precocious Puberty of P · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03915795 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Hospital of Fudan University
- Last refreshed: 8 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03915795.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing